Session Details

P019 Diagnosis and Management of Cutaneous Lymphomas: Cases from Multidisciplinary Clinics for the General Derm

Sat, Aug 3, 1:00 PM - 3:00 PM
607
2 CME Available 2 Hour Parallel
View Map

DESCRIPTION

In this session, cutaneous lymphoma experts will use real-life cases from their multidisciplinary cutaneous lymphoma clinics to illustrate best practices for diagnosing and managing cutaneous B-cell and cutaneous T-cell lymphoma. Emphasis will be placed on practical tips, including:

-How T-cell gene rearrangements can help aid in diagnosis of CTCL
-How to stage a new patient with suspected CTCL
-Skin-directed therapies for CTCL, including how to prescribe topical nitrogen mustard
-Oral therapies for CTCL
-Treatments for advanced CTCL, and when to refer to an oncologist
-Emerging therapies for CTCL
-Non-MF/SS CTCLs and when to suspect these more aggressive lymphomas

LEARNING OBJECTIVES

1.

Identify some of the most common and “don’t miss” subtypes of cutaneous lymphoma seen by the general dermatologist.

2.

Discuss strategies for accurate diagnoses of cutaneous lymphomas, including the use of molecular techniques (flow cytometry and clonality).

3.

Outline a treatment strategy for early stage and for advanced stage CTCL.

SCHEDULE

8:00 PM

Cases from the Multidisciplinary Cutaneous Lymphoma Clinic

SPEAKERS

Jina Chung, MD, FAAD

Jina Chung, MD, FAAD

Cecilia Larocca, MD, FAAD

Cecilia Larocca, MD, FAAD

Christiane Querfeld, MD, PhD, FAAD

Christiane Querfeld, MD, PhD, FAAD

City of Hope Comprehensive Cancer Center and Beckman Research Institute

Michi Shinohara, MD, FAAD

Michi Shinohara, MD, FAAD

SPEAKER DISCLOSURES

Jina Chung, MD, FAAD

No financial relationships exist with ineligible companies.

Cecilia Larocca, MD, FAAD

No financial relationships exist with ineligible companies.

Christiane Querfeld, MD, PhD, FAAD

Citius Pharmaceuticals – Advisory Board(Honoraria); Helsinn Healthcare – Advisory Board(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Investigator(Fees), Investigator(Grants/Research Funding); Kyowa Kirin – Advisory Board(Honoraria); Mallinckrodt Pharmaceuticals – Advisory Board(Honoraria);

Michi Shinohara, MD, FAAD

Kyowa Hakko Kirin Pharma, Inc. – Consultant (1099 relationship)(Fees); Kyowa Kirin – Investigator(Grants/Research Funding);